Navigation Links
Newer Blood Pressure Drug Better for Some Heart Patients, Diabetics
Date:8/31/2008

Study found telmisartan offered slight benefit for those unable to take ACE inhibitors

SUNDAY, Aug. 31 (HealthDay News) -- A new study offers a possible alternative to heart patients and diabetics who need to keep their blood pressure under control but who cannot tolerate the standard treatment of ACE inhibitors.

Reporting at the European Society of Cardiology in Munich on Sunday, Canadian researchers said they found that the angiogenesis-receptor blocker (ARB) known as telmisartan worked well for the 20 percent of patients with vascular disease and high-risk diabetes who can't take ACE inhibitors. The study was released in the Aug. 31 online issue of The Lancet to coincide with the meeting presentation.

In the randomized, controlled trial, almost 6,000 patients with vascular disease or high-risk diabetes took either telmisartan or a placebo, and were followed for almost five years. Rates of death, heart attack, stroke or hospitalization for heart failure were tracked as primary outcome measures during the study period.

Mean blood pressure was lower in the telmisartan group by 4.0/2.2 mm/Hg, and there was a relative risk reduction of 13.3 percent for those taking telmisartan. Fewer patients on the medication wound up in the hospital for cardiovascular problems (30.3 percent), compared to those on placebo (33 percent).

"These data suggest that telmisartan confers a modest benefit when added to other proven therapies," the researchers wrote in a news release from the journal. "In view of the drug's tolerability and effect on cardiovascular endpoints, telmisartan could be regarded as a potential treatment for patients with vascular disease or high-risk diabetes, if they are unable to tolerate an ACE inhibitor."

However, an accompanying commentary from U.S. experts dampened the significance of the finding.

"ARBs that have been studied in coronary disease are safe, but possibly less effective alternatives in patients with intolerance to ACE inhibitors. Although data are too limited to reach definitive conclusions, the clinical effect of ARBs seems less robust than that of ACE inhibitors," wrote Dr. Toni Ripley and Dr. Donald Harrison, from the University of Oklahoma College of Pharmacy.

And U.S. researchers reported on Wednesday that telmisartan does not lower the rate of stroke, cardiovascular events or diabetes better than a placebo in patients who have had a stroke.

More information

For more on ARBs, go to U.S. Food and Drug Administration.



-- HealthDay staff



SOURCE: The Lancet, news release, Aug. 31, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Newer Blood Pressure Drug No Better Than Placebo in Preventing Stroke
2. Newer Prostate Cancer Treatment Similar to Traditional Surgery
3. Newer Rheumatoid Arthritis Drugs Lower Production of B Cells
4. Newer Sedative Might Help Patients on Ventilators
5. Newer Anticlotting Drug Safe, Effective for Heart Surgeries
6. Newer radiation treatment easier for some throat cancer patients
7. Newer Antibiotic Speeds TB Healing
8. Newer antidepressants led to less, not more, teen suicides
9. Most Patients With Irregular Heartbeat Take Inadequate Blood Thinner Dose
10. Finding May Allow Some Women to Stop Blood Thinners
11. For Rare Blood Disorder, Pumping Iron Is the Cure
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Newer Blood Pressure Drug Better for Some Heart Patients, Diabetics
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Source Vitál ... and 100 percent pure essential oils, announced the company had a successful visit to ... The annual ECRM event gives companies that work in the nutritional, sports and health ...
(Date:1/20/2017)... ... January 20, 2017 , ... Lice Troopers, the lice ... in families with school-aged children since the holiday season. , “It happens every ... their families, sharing hugs and taking photos, which is the head-to-head gateway that lice ...
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser celebrated 5 ... For Betsy, the clinical trial has been life-saving as she has been on ... , Betsy Brauser was diagnosed with ovarian cancer in 2009. She underwent standard chemotherapy ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Mary Magdalene: Grace is Greater than ... the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” ... career as an educator interacting with countless women who had little knowledge of the ...
(Date:1/20/2017)... ... ... You”: a fine examination of how God handles sin, including how to let go ... Miller, who, for over ten long years has been waiting to release this powerful insight ... he has been serving the Lord for over twenty years, and he has been preaching ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 19, 2017 New Review ... Address Motor Symptoms and Motor Complications in Mid- ... ... (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) C ... Neurological Review,2016;11(Suppl. 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late ...
(Date:1/19/2017)... Marks E-QURE , s 3 ... similar agreements in Israel and Argentina ... 5 billion global market ... medical devices for the treatment of advanced wound care, announced today it signed ... Colombia for the Company,s patented Bio-electrical Signal Therapy device ("BST ...
(Date:1/19/2017)... Jan. 18, 2017  Magnetic Insight Inc., leader ... into an agreement with inviCRO LLC to develop ... imaging system based on inviCRO,s VivoQuant™ visualization and ... as a complete MPI solution package with the ... or cell imaging in vivo. MPI ...
Breaking Medicine Technology: